Results from Study Utilizing Champions TumorGraft® PDX Models in Abstract Published in Conjunction with ASCO Annual Meeting

Hackensack, NJ – May 29, 2015 – Champions Oncology, Inc. (OTC : CSBR) a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the publication of data gained collaboratively with the Angeles Clinic and Research Institute in Los Angeles in conjunction with the 2015 American Society of Clinical Oncologists Annual Meeting.

The preliminary data, from an on-going initiative at The Angeles Clinic and Research Institute using Champions TumorGraft® patient-derived xenograft (PDX) models to improve the selection of effective treatment options for patients with advanced cancers, will be included in an abstract entitled,” Selecting Optimal Patient Candidates to Assess the Clinical Utility of Patient- Derived Xenograft (PDX) models in Advanced Solid Tumors.”

In 2014, The Angeles Clinic and Research Institute in Los Angeles announced it was expanding its personalized oncology services by using Champions TumorGraft® PDX models  The Champions Oncology TumorGraft process includes the removal of a piece of the patient’s living tumor during surgery or biopsy and engrafting it in immune-deficient mice.  After the PDX model grows, still closely resembling the patient’s tumor, Champions Oncology tests drug treatment in the model and measures the response.  Champions TumorGraft PDX models have demonstrated high rates of predictability using multiple therapies, including single-agent and combination, chemotherapy regimens and targeted biological drugs, with data previously published in Cancer and Cancer Clinical Research.

Banked Champions TumorGraft PDX models can be re-grown and tested in the event of cancer progression or recurrence.  They have successfully be utilized in most sold tumor types including colorectal, ovarian, lung, breast, sarcoma, pancreatic, stomach, esophageal, and others.